Marco Metra
Marco Metra, MD is an expert in Cardiology at Spedali Civili di Brescia (Italy). As of October 2026, ScienceLeadR ranks Marco Metra in the top 1% of experts worldwide for Heart Failure, Mitral Valve Insufficiency and Cardiomyopathies. Marco Metra has authored 1,743 publications, the most recent in 2026, and is an investigator in 61 clinical trials, 7 of them ongoing. SLR score: 6,768 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Public Health - Biostatistics - Internal Medicine
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Marco Metra, MD
Full Professor of Cardiology
Cardiology. IRCCS San Raffaele Scientific institute. Milan
Vita-Salute San Raffaele University. Milan. Italy
Marco Metra is Full professor of cardiology at the Vita-Salute San Raffaele University and directs the Clinical Cardiology and Invasive Cardiology Unit of the IRCCS San Raffaele Scientific Institute of Milan, Italy. He was former Director of the Institute of Cardiology of the Civil Hospital and University of Brescia, Italy, since November 2012 and Full Professor of Cardiology at the University of Brescia, Italy, since December 2015. He was Editor-in-Chief of the European Journal of Heart Failure, from November 2015 to April 2021. He is Editor-in-Chief European Heart Journal – Valvular and Structural Heart Disease since August 2025. He is President of the Heart Failure Association of the European Society of Cardiology since April 2024.
Marco Metra received his medical degree in 1981 and then received the post-graduate fellowships in Internal Medicine and in Cardiology, at the University of Parma. He was a research associate at the Committee on Clinical Pharmacology of the University of Chicago, Illinois, (Director, Prof. Leon I. Goldberg), in 1985, returning to work at the Cardiology Institute of the University of Brescia in 1986. He was appointed Associate Professor of Cardiology in 2001 and then became Full Professor of Cardiology in 2015 at the University of Brescia.
Prof. Metra has been principal investigator and member of the Executive or Steering Committees of many trials in patients with heart failure. He is co-chair of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2023 ESC HF guidelines update
Prof Metra served as board member of the HFA of ESC from 2001 to 2008, being secretary of the executive board from 2004 to 2006 and then served as ex-officio member of the HFA board from 2015 and then as President elect since 2022. He has also been a member of the ESC’s Committee for Practice Guidelines in the years 2004 to 2008, member of the ESC Congress Program Committee in the years 2008-2012 and 2023.
He is author of more than 1700 articles in peer-reviewed journals, current scopus H-index, 129, google scholar H index, 143, ranking 48 in the Top Italian Scientists Biomedical Sciences rank https://topitalianscientists.org/TIS_HTML/Top_Italian_Scientists_Biomedical_Sciences.htm
Organizations
Career arc: 1988 - 2026
Number : 1743
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 61
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 5
Ongoing Clinical Trials
7 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| HF POLARIS A research study to look at how well NNC0487 0111 works compared to placebo in people with heart failure and obesity 2025-523717-29-00 — mortality, safety, heart failure, heart, heart failure, diastolic, obesity, morbidity, research | Phase 3 | Recruiting | 2026 |
| Bempedoic acid ezetimibe high intensity statin in patients without cardiovascular events 2025-524625-41-00 — ezetimibe, atherosclerosis, hydroxymethylglutaryl-coa reductase inhibitors | Phase 3 | Not yet recruiting | 2026 |
| Metabolic Exercise Test Data Combined with Cardiac and Kidney Indexes (MECKI) Score Evolution Identification of Cardiovascular Risk in Patients with Heart Failure NCT06884631 — exercise, heart failure, exercise test, heart, kidney, therapeutics, prognosis | N/A | Recruiting | 2021 |
| European Registry of Transcatheter Repair for Tricuspid Regurgitation NCT06307262 — registries, heart valve diseases, heart diseases, heart failure, heart, tricuspid valve, tricuspid valve insufficiency, heart valves | N/A | Recruiting | 2023 |
| A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non Obstructive Hypertrophic Cardiomyopathy (nHCM) NCT06081894 — safety, multiple chronic conditions, tablets, cardiomyopathy, hypertrophic, cardiomyopathies | Phase 3 | Active not recruiting | 2023 |
LeadR Networks
Main global connection map